Myeloma Canada has initiated a special Multiple Myeloma March (MMM) Research Fund-sharing Partnership Program. Program applicants can qualify to partner with Myeloma Canada on their nearest MMM and be awarded a research grant of up to 50% of the net MMM proceeds.

Applicants must be a charitable organization that is associated with a Canadian myeloma treatment centre or university that conducts myeloma research (i.e., hospital foundation; university foundation). Applicants must work with at least one myeloma researcher to prioritize and agree upon the project(s) or research-related initiative(s) that will be submitted within the application. Only one (1) research grant (for one or more projects) will be awarded per MMM. Research grant funds will be provided in Q1 2025.

All submitted projects or initiatives within applications must be: 

• for one year of funding;
• conducted and/or supervised by a myeloma researcher, at any career stage, that is affiliated with a Canadian university, hospital, cancer centre, or research institute. The research may include collaborations with affiliated myeloma researchers outside Canada; however, awarded research grant funds may not be used to fund patient research outside Canada.

All research projects and research-related initiatives will be evaluated by an independent review committee to determine their relevance to Myeloma Canada’s Funded Research Principals & Priorities.

Research projects and research-related initiatives that may be submitted within an application include, but are not limited to: 

• Research projects: Academic research, bench research, or clinical research.
• Research-related initiatives: Equipment/technology costs, biobanking costs, or database costs.

Awarded funding does not necessarily need to cover a specific project or initiative in its entirety; however, a budget breakdown will be required to outline how the research grant funds will be used.